Cambrex to Buy Avista Pharma Solutions

02:40 EST 22 Nov 2018 | CHEManager

Cambrex Corporation, which bills itself as the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has agreed to acquire Avista Pharma Solutions, a contract development, manufacturing and testing organization (CDMO), from private equity investor Ampersand Capital Partners for about $252 million. 

Original Article: Cambrex to Buy Avista Pharma Solutions


More From BioPortfolio on "Cambrex to Buy Avista Pharma Solutions"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...